Stockreport

Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the Management of Postoperative Pain

Avenue Therapeutics, Inc.  (ATXI) 
Last avenue therapeutics, inc. earnings: 8/14 07:30 am Check Earnings Report
PDF NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intraveno [Read more]